Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Yisheng Bio Raises $40 Million in a Royalty-based Funding from CBC Affiliate

publication date: Mar 23, 2022

Beijing YishengBio completed a $40 million Series C round in a royalty-based transaction with R-Bridge, a division of CBC Group focused on royalty transactions. Founded in 1994, Yisheng develops products based on its PIKA immunomodulatory adjuvant for vaccines, cancer and infectious diseases. The PIKA technology increases innate and adaptive immune responses via the TLR3, RIG-I and MDA5 pathways. The company has also developed a COVID-19 vaccine with potential for therapeutic use that is undergoing clinical trials. One year ago, YishengBio closed a $130 million B round led by OceanPine and OrbiMed. More details....

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital